115 related articles for article (PubMed ID: 9741997)
1. Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907.
Witkin J; Gasior M; Acri J; Beekman M; Thurkauf A; Yuan J; DeBoer P; Wikström H; Dijkstra D
Eur J Pharmacol; 1998 Apr; 347(2-3):R1-3. PubMed ID: 9741997
[TBL] [Abstract][Full Text] [Related]
2. The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors.
Witkin JM; Levant B; Zapata A; Kaminski R; Gasior M
J Pharmacol Exp Ther; 2008 Sep; 326(3):930-8. PubMed ID: 18566292
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
van Vliet LA; Rodenhuis N; Dijkstra D; Wikström H; Pugsley TA; Serpa KA; Meltzer LT; Heffner TG; Wise LD; Lajiness ME; Huff RM; Svensson K; Sundell S; Lundmark M
J Med Chem; 2000 Jul; 43(15):2871-82. PubMed ID: 10956195
[TBL] [Abstract][Full Text] [Related]
4. Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907].
Witkin JM; Dijkstra D; Levant B; Akunne HC; Zapata A; Peters S; Shannon HE; Gasior M
J Pharmacol Exp Ther; 2004 Mar; 308(3):957-64. PubMed ID: 14711932
[TBL] [Abstract][Full Text] [Related]
5. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
6. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D3 agonists disrupt social behavior in rats.
Kagaya T; Yonaga M; Furuya Y; Hashimoto T; Kuroki J; Nishizawa Y
Brain Res; 1996 May; 721(1-2):229-32. PubMed ID: 8793104
[TBL] [Abstract][Full Text] [Related]
8. Effects of adenosine A(2A) receptor stimulation in vivo on dopamine D3 receptor agonist binding in the rat brain.
Hillefors M; Hedlund PB; von Euler G
Biochem Pharmacol; 1999 Dec; 58(12):1961-4. PubMed ID: 10591151
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2 receptors play a role in the (-)-apomorphine-like discriminative stimulus effects of (+)-PD 128907.
Kleven MS; Koek W
Eur J Pharmacol; 1997 Feb; 321(1):1-4. PubMed ID: 9083778
[TBL] [Abstract][Full Text] [Related]
10. The D2/D3 agonist PD128907 (R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol) inhibits stimulated pyloric relaxation and spontaneous gastric emptying.
Kashyap P; Micci MA; Pasricha S; Pasricha PJ
Dig Dis Sci; 2009 Jan; 54(1):57-62. PubMed ID: 18600456
[TBL] [Abstract][Full Text] [Related]
11. The Role of Dopamine D
Huang M; He W; Kiss B; Farkas B; Adham N; Meltzer HY
J Pharmacol Exp Ther; 2019 Nov; 371(2):517-525. PubMed ID: 31511365
[TBL] [Abstract][Full Text] [Related]
12. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; turning behaviour.
Koshikawa N; Kitamura M; Kobayashi M; Cools AR
Eur J Pharmacol; 1996 Jul; 308(3):235-41. PubMed ID: 8858293
[TBL] [Abstract][Full Text] [Related]
13. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
14. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice.
Koeltzow TE; Xu M; Cooper DC; Hu XT; Tonegawa S; Wolf ME; White FJ
J Neurosci; 1998 Mar; 18(6):2231-8. PubMed ID: 9482807
[TBL] [Abstract][Full Text] [Related]
15. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
[TBL] [Abstract][Full Text] [Related]
16. Cocaine sensitization prevents the hypolocomotor effects of high but not low doses of PD 128,907.
Prinssen EP; Koek W; Kleven MS
Eur J Pharmacol; 1998 Aug; 355(1):19-22. PubMed ID: 9754934
[TBL] [Abstract][Full Text] [Related]
17. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
[TBL] [Abstract][Full Text] [Related]
18. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; jaw movements.
Koshikawa N; Miwa Y; Adachi K; Kobayashi M; Cools AR
Eur J Pharmacol; 1996 Jul; 308(3):227-34. PubMed ID: 8858292
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys.
Achat-Mendes C; Grundt P; Cao J; Platt DM; Newman AH; Spealman RD
J Pharmacol Exp Ther; 2010 Aug; 334(2):556-65. PubMed ID: 20494958
[TBL] [Abstract][Full Text] [Related]
20. Discriminative stimulus properties of the putative dopamine D3 receptor agonist, (+)-PD 128907: role of presynaptic dopamine D2 autoreceptors.
Bristow LJ; Cook GP; Patel S; Curtis N; Mawer I; Kulagowski JJ
Neuropharmacology; 1998 Jun; 37(6):793-802. PubMed ID: 9707293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
